Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials

Joshua Tobina Neurosciences Clinic, Banner University Medical Center, Phoenix, AZ, USACorrespondence[email protected]

Janet H. Fordb Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA

Antje Tockhorn-Heidenreichc Eli Lilly and Company, Bracknell, UK

Russell M. Nicholsb Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA

Wenyu Yeb Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA

Rohit Bhandarib Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA

Xiaojuan Mib Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA;d TechData Service Company, King of Prussia, PA, USA

Karan Sharmab Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA

Richard B. Liptone Albert Einstein College of Medicine, Bronx, NY, USA

Your download is now in progress and you may close this window